Pipeline

Publications

Cosibelimab (CK-301) Anti-PD-L1 Reference Articles & Poster Presentations

Clingan, P., et al. Cosibelimab, an Anti-PD-L1 Antibody, in Metastatic Cutaneous Squamous Cell Carcinoma (CSCC): Preliminary Safety and Efficacy Results from a Phase 1 Clinical Trial. European Society for Medical Oncology (ESMO) Congress. 2020-09-17 Poster 1084P. (View Cosibelimab ESMO 2020 Poster)

Clingan, P., et al. Safety, Efficacy and Pharmacokinetic Profile of Cosibelimab, an Anti-PD-L1 Antibody, in Patients with Advanced Cancers. European Society for Medical Oncology (ESMO) Congress. 2019-09-28 Poster 469P. (View Cosibelimab ESMO Poster)

Gorelik, L., et al.  Preclinical characterization of a novel fully human IgG1 anti-PD-L1 mAb CK-301. American Association for Cancer Research Annual Meeting (AACR). 2016-04-04 Abstract 4606. (View CK-301 AACR Poster)

Harris, D., et al. Cosibelimab, an anti-PD-L1 antibody: Preliminary Safety and Efficacy Results from a Global, Multicohort Phase 1 Clinical Trial. Society for Immunotherapy of Cancer (SITC) 35th Annual Meeting. 2020-11-09 Poster 399. (View SITC 2020 Meeting Poster)

Lin, L., et al. Semi-mechanistic PK and target-occupancy modeling to support dose justification for anti-PD-L1 clinical candidate CK-301 (cosibelimab) in oncology patients. Society for Immunotherapy of Cancer (SITC) 34th Annual Meeting. 2019-11-08 Abstract P431 (View SITC 2019 Meeting Poster)

CK-101 EGFR Inhibitor Reference Articles & Poster Presentations

Johnson, M., et al. CK-101 (RX518), a Third Generation Mutant-Selective Inhibitor of EGFR in NSCLC: Results of an Ongoing Phase I/II Trial. International Association for the Study of Lung Cancer (IASLC) 19th World Conference on Lung Cancer. 2018-09-24 Abstract. (View CK-101 Data Presentation)

Qian, X., et al. CK-101 (RX518), a mutant-selective inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC. American Association for Cancer Research Annual Meeting (AACR). 2016-04-03 Abstract 2078. (View CK-101 AACR Poster)

CK-103 BET Inhibitor Reference Articles & Poster Presentations

Normant, E., et al. TG-1601 is a novel BET inhibitor with strong binding affinity and long-lasting effect in pre-clinical models. American Association for Cancer Research Annual Meeting (AACR). 2018-04-18 Abstract 5790. (View CK-103 AACR Poster)

Anti-CAIX Reference Articles

Xu, C. et al. Unique biological properties of catalytic domain directed human anti-CAIX antibodies discovered through phage-display technology. PLoS One 5, e9625 (2010).

Chang, D.-K. et al. Human anti-CAIX antibodies mediate immune cell inhibition of renal cell carcinoma in vitro and in a humanized mouse model in vivo. Mol. Cancer 14, 119 (2015).